GC Cell, a fully integrated cell therapy pioneer, has announced poster presentations from studies of its preclinical study of GL205 (GCC2005), a CD5 CAR-NK targeting malignant T-cell lymphoma, and real-world data for the anticancer immunotherapy drug ‘Immuncell-LC’ at the AACR Annual Meeting 2024 th
Hanmi Pharmaceutical announced on March 18 that it will unwrap 10 new research projects, the most in the industry, in the American Association for Cancer Research 2024 (AACR 2024), which will run in San Diego of the United States from April 5 to 10.First, Hanmi Pharmaceutical will present the result
SillaJen announced on Jan. 1 that it has applied to the U.S. Food and Drug Administration (FDA) for approval to amend the Investigational New Drug (IND) application for Phase 1 clinical trials of its BAL0891 cancer drug candidate.BAL0891 is a mitotic checkpoint inhibitor (MCI) class anticancer drug
Orion is taking its first step into the next-generation anti-cancer drug market by acquiring LegoChem Bio for about 55 billion won.Orion Holdings acquired a 25 percent stake in LegoChem Bio and became the largest shareholder on Jan. 15, according to industry sources on Jan. 16. Orion acquired a tota
Yuhan Pharmaceuticals’ lung cancer drug Leclaza has demonstrated enhanced efficacy when combined with Johnson & Johnson’s (J&J) lung cancer treatment. Detailed data is set to be presented at a global conference on Oct. 23, heightening market anticipation.According to industry sources on Oct. 4, Yuha
Celltrion announced on Sept. 19 that it is focusing on securing various platforms and pipelines including oral antibody therapeutics, antibody drug conjugates (ADCs), new antibody drugs, bispecific antibodies, microbiomes and anti-cancer virus platforms through development and research as well as op
TiumBio Co., Ltd. (KRX: 321550. KQ), a clinical-stage biopharmaceutical company focusing on discovering and developing innovative therapeutics for patients with rare and incurable diseases, today announced that the Phase 1a results of TU2218 will be presented at the 2023 European Society of Medical
The trend of collaborations between domestic and foreign enterprises of various sizes to achieve success in new drug development is on the rise. Such collaborations are viewed within the industry as a potential model for “Korean-style Open Innovation” in the pharmaceutical and biotech sectors.Accord
Nine merger and acquisition (M&A) deals worth more than US$1 billion were made in the global pharmaceutical and bio industries in the first half of this year.According to the Korea Biotechnology Industry Organization (KBIO) on July 2, the global pharmaceutical and bio industries recorded nine M&A de
SK pharmteco, SK Inc.’s contract development manufacturing organization (CDMO) for pharmaceuticals, successfully completed its second facility for Cell and Gene Therapies (C>) manufacturing in Europe. With this milestone, SK pharmteco is rapidly expanding its presence in the global market.SK pharm
CJ Bioscience, an affiliate of CJ CheilJedang, announced on April 13 that it would present a poster of the results of preclinical trials on CJRB-101 at the American Association for Cancer Research (AACR) 2023, one of the world’s top three cancer societies. CJRB-101 is a new drug candidate (pipeline)
Technology exports from the domestic pharmaceutical and biotech sector totaled eight cases in the first quarter of this year. The scale of the five open contracts is 2.169 trillion won (US$1.643 billion). In the first quarter of last year, the figures were six and 2.174 trillion won (US$1.647 billio
TiumBio Co., an R&D-focused clinical-stage biotechnology company based in South Korea, today announced the publication of two posters that will be presented during the upcoming 2023 American Association for Cancer Research Annual Meeting (AACR 2023), taking place from April 14th in Orlando, Florida.
Chong Kun Dang announced on Feb. 3 that it has licensed antibody-drug conjugate (ADC) technology from Synaffix B.V., a Dutch biotechnology company.The contract amount is approximately US$132 million including the down payment and development, licensing and sales milestones.With this contract, Chong
Protium Science, a contract development and analysis organization (CDAO) in Korea, announced that it has signed a contract development and analysis service agreement with MUSTBIO, a biotechnology company specializing in multi-specific antibody platforms.Under the agreement, Protium Science, as a CDA
Daewoong Pharmaceutical announced on Jan. 5 that it signed a contract with Oncorus of the United States on Jan. 4 for joint R&D and commercialization of lipid nanoparticle (LNP) mRNA drugs.Oncorus is a U.S. a biopharmaceutical company focused on developing next-generation RNA-based immunotherapies.T
LG Chem is expected to successfully take over Aveo Pharmaceuticals, a U.S. anti-cancer drug development company, next year and enter the U.S. market.LG Chem’s acquisition of Aveo is expected to close within the first quarter of 2023. The company announced on Oct. 18 that it would acquire a 100 perce
The author is an analyst of NH Investment & Securities. He can be reached at pk.park@nhqv.co. -- Ed. SK Biopharm posted consolidated 3Q22 sales of W88.8bn and an operating loss of W9.2bn, beating consensus. The firm’s operating loss narrowed on the booking of W19.6bn in licensing out fees for Cenoba
JW Group announced on Nov. 1 that it has signed a joint research contract with KURE.AI Therapeutics, a U.S. biotech venture company, to develop innovative anticancer therapies based on artificial intelligence (AI).Under this contract, JW Pharmaceutical and JW CreaGene will start R&D activities for t
LG Chem announced on Oct. 18 that it has decided to acquire AVEO Pharmaceuticals in the United States. The U.S. drugmaker has a patent on a kidney cancer treatment. This will mark the first time for a Korean company to take over a company that has developed a new drug approved by the U.S. Food and D